1. トップ >
  2. Medical Affairs Website >
  3. 精神領域Publication一覧

精神領域Publication一覧

最終更新：2025/4

こちらには弊社社員が著者に含まれる論文や、弊社から資金提供・原薬提供などを行った研究論文を掲載しています。

精神領域

2025開く

    ＜英文＞

  • Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia

    D. Nemoto et al. Drug Metabolism and Pharmacokinetics 2025;60 101043

2024開く

    ＜英文＞

  • Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial

    H.Takeuchi et al. J Clin Psychopharmacol. 2024 00;00. doi: 10.1097/JCP.0000000000001943

  • Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms

    Y.Takekita et al. Neuropsychopharmacol Rep. 2024;00:1-8

  • Chronic treatment with the antipsychotic lurasidone modulates the neuroinflammatory changes associated with the vulnerability to chronic mild stress exposure in female rats

    V. Begni et al. Brain, Behavior, and Immunity 2024;123 586-596

  • The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults.

    Citrome L et al. International Clinical Psychopharmacology 2024 Jul 22. doi: 10.1097/YIC.0000000000000563. Online ahead of print.

  • Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study.

    H.Maruyama et al. Neuropsychiatric Disease and Treatment 2024:20 1453–1463

  • Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies.

    Calisti F et al. Ann Gen Psychiatry. 2024 Jul 18;23(1):26.

  • Efficacy and safety of adding lurasidone to ongoing therapy with lithium or valproate for the treatment of an acute bipolar depressive episode.

    Tocco M et al. J Clin Psychopharmacol. 2024 Jul-Aug;44(4):345-352. doi: 10.1097/JCP.0000000000001850. Epub 2024 Apr 19.

  • Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone

    Kubota R et al. Front. Psychiatry. 2024 14:1331356.

  • Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study

    Miura I et al. J Clin Psychiatry. 2024 Jan 31;85(1):23m14881.

  • Factors associated with death, hospitalization, resignation, and sick leave from work among patients with schizophrenia in Japan: a nested case–control study using a large claims database

    Inada K et al. BMC Psychiatry. 2024 24:22.

  • Transcriptomic analyses of rats exposed to chronic mild stress:Modulation by chronic treatment with the antipsychotic drug lurasidone.

    Begni V. et al. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Feb 8:129:110885.

    • ＜和文＞

  • 双極症患者の認知機能に対する精神科医アンケート調査

    奥村みゆき , 増田孝裕, 遠矢俊司 , 中川伸 (山口大学大学院医学系研究科　高次脳機能病態学講座)　| 最新精神医学 29巻 5号, 325-334, 2024

  • 統合失調症患者の認知機能に対する精神科医アンケート調査

    篠原温美 , 遠矢俊司 ，髙井健太郎 , 増田孝裕, 中川伸 (山口大学大学院医学系研究科)｜最新精神医学 29巻 4号，263-272，2024

  • 日本人統合失調症患者を対象としたblonanserin テ-プ製剤長期投与におけるresolution/remission の出現の推移と治療継続率 2 つの長期臨床試験のpost hoc 解析

    井上 善文, 石郷岡 純, 中村 洋, ほか　臨床精神薬理 Volume 27, Issue 8, 859 - 875 , 2024

2023開く

    ＜英文＞

  • Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

    Wei YM et al. World J Psychiatry. 2023 Nov 19;13(11):937-948.

  • Reduced sociability in a prenatal immune activation model: Modulation by a chronic blonanserin treatment through the amygdala-hippocampal axis.

    Deriha K. et al. J　Psychiatric Resarch. 2023;164(6):209-220

  • Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression.

    Singh M. et al. Curr Neuropharmacol. 2023;21(6):1393-1404.

  • The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis

    Goldberg J. et al. J Clin Psychiatry 2023;84(4):22m14732

  • The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials.　

    M. Kato et al. J Affect Disord. 2023 Sep 15;337:150-158.

  • In Vitro Assessment of Compounded Lurasidone Suspensions for Enternal Feeding Tube.

    J. Wojcinski et al. Hosp Pharm. 2023 Jun;58(3):304-308.

  • A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression.

    T.Kishi et al. Neuropsychopharmacol Rep. 2023 Mar;43(1):137-140.

2022開く

    ＜英文＞

  • Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study.

    I.Miura et al. Neuropsychiatr Dis Treat. 2022 Nov 9;18:2627-2637.

  • Exposure to chronic stress impairs the ability to cope with an acute challenge: Modulation by lurasidone treatment.

    V.Begni et al. Eur Neuropsychopharmacol. 2022 Aug;61:78-90.

  • Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test.

    T.Kishi et al. Psychiatry Clin Neurosci. 2022 Aug;76(8):401-402.

  • Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.

    Chengcheng Pu et al. BMJ Open. 2022 Apr 20;12(4):e054079.

  • Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.

    Melissa P. DelBello et al. J Am Acad Child Adolesc Psychiatry. 2022 Feb;61(2):243-254.

  • Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.

    K.Ohi et al. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 8;113:110470.

  • Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.

    T.Saito et al. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):12-23.

  • Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.

    T.Kishi et al. Schizophr Res. 2022 Feb;240:231-232.

  • Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.

    T.Saito et al. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):24-35.

  • Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey.

    K.Baba et al. BMC Psychiatry. 2022 Jun 18;22(1):410.

    • ＜和文＞

  • 【二次出版】統合失調症患者におけるlurasidoneの安全性及び有効性　12週間非盲検継続投与試験

    伊豫雅臣ら　臨床精神薬理, 2022, 25巻5号 P.573-590.

  • 【二次出版】青年期統合失調症患者を対象としたblonanserin経口剤の長期投与による安全性と有効性の検討　検証試験から継続した52週間多施設共同非盲検長期投与試験

    齊藤卓弥ら　臨床精神薬理, 2022, 25巻6号 P.719-736.

  • 【二次出版】青年期統合失調症患者を対象としたblonanserin経口剤の有効性と安全性の検討　6週間ランダム化プラセボ対照試験

    齊藤卓弥ら　臨床精神薬理, 2022, 25巻6号 P.701-718.

  • 統合失調症患者を対象としたblonanserin経皮吸収型テープ製剤の適用部位皮膚関連有害事象の検討　一般使用成績調査の結果と追加解析

    中村洋ら　臨床精神薬理, 2022, 25巻4号 P.435-454.

  • 【二次出版】日本人の双極I型障害患者を対象としたlurasidoneの長期投与試験　52週間非盲検試験

    樋口輝彦ら　臨床精神薬理, 2022, 25巻3号 P.333-349

  • 【二次出版】急性増悪期の統合失調症患者におけるlurasidoneの有効性および安全性　6週間、ランダム化、二重盲検、プラセボ対照試験

    伊豫雅臣ら　臨床精神薬理, 2022, 25巻2号 P.205-220

2021開く

    ＜英文＞

  • Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis.

    T.Kishi et al. Psychopharmacology (Berl). 2021 Dec;238(12):3585-3593.

  • Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.

    M.Iyo et al. Neuropsychiatr Dis Treat. 2021 Aug 16;17:2683-2695.

  • Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study.

    T.Higuchi et al. Int J Bipolar Disord. 2021 Aug 2;9(1):25.

  • Stress Modifies the Expression of Glucocorticoid-Responsive Genes by Acting at Epigenetic Levels in the Rat Prefrontal Cortex: Modulatory Activity of Lurasidone.

    P.Brivio et al. Int J Mol Sci. 2021 Jun 8;22(12):6197.

  • Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.

    A.Kadakia et al. BMC Psychiatry. 2021 May 11;21(1):249.

  • Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study.

    M.Iyo et al. Psychiatry Clin Neurosci. 2021 Apr 23;75(7):227-35.

  • Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients.

    T.Sakayori et al. Psychopharmacology (Berl). 2021 May;238(5):1343-1350.

  • Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies.

    M.Murasaki et al. Ann Gen Psychiatry. 2021 Sep 7;20(1):41.

  • Impact of bipolar disorder on health-related quality of life and work productivity: Estimates from the national health and wellness survey in Japan.

    T.Kato et al. J Affect Disord. 2021 Dec 1;295:203-214.

  • Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.

    T.Kishimoto et al. Lancet Psychiatry. 2021 May;8(5):387-404.

  • Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis.

    K.Hagi et al. JAMA Pshychiatry. 2021 May 1 ; 78(5): 510-518

  • Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials.

    I.Miura et al. Int J Neuropsychopharmacol. 2021 Mar 17;24(3):200-215.

  • Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study.

    J.Ishigooka et al. J Affect Disord. 2021 Feb 15;281:160-167.

  • Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.

    Y.Inoue et al. J Pharmacol Sci. 2021 Jan;145(1):42-51.

    • ＜和文＞

  • Lurasidoneの双極I型障害の抑うつエピソードの患者を対象とした第III相試験(ELEVATE試験)の部分集団解析　日本の実施医療機関で集積された被験者データの傾向

    加藤忠史ら　臨床精神薬理, 2021, 24巻12号 P.1265-1275

  • 【二次出版】Lurasidoneの抑うつエピソードを伴う双極I型障害患者に対する長期投与試験:28週間非盲検継続投与試験

    石郷岡純ら　臨床精神薬理, 2021, 24巻10号 P.1049-1071

  • 【二次出版】抑うつエピソードを伴う双極I型障害患者に対するlurasidone単剤治療　ランダム化プラセボ対照二重盲検比較試験

    加藤忠史ら　臨床精神薬理, 2021, 24巻4号 P.387-405

2020開く

    ＜英文＞

  • Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression.

    T.Kato et al. Psychiatry Clin Neurosci. 2020 Dec;74(12):635-644.

  • Long-term effects of stress early in life on microRNA-30a and its network: Preventive effects of lurasidone and potential implications for depression vulnerability.

    A.Cattaneo et al. Neurobiol Stress. 2020 Nov 23;13:100271.

  • Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.

    T.Kishi et al. Neuropsychopharmacol Rep. 2020 Sep;40(3):314-322.

  • Effect of lurasidone treatment on chronic mild stress-induced behavioural deficits in male rats: The potential role for glucocorticoid receptor signalling.

    F.Calabrese et al. J Psychopharmacol. 2020 Apr;34(4):420-428.

  • A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.

    T.Niitsu et al. Asian J Psychiatr. 2020 Oct;53:102369.

  • Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database.

    Y.Takekita et al. Neuropsychiatr Dis Treat. 2020 Nov 30;16:2871-2879.

  • A propensity score matching analysis for cardio metabolic risk of antipsychotics in patients with schizophrenia using Japanese claims data.

    I.Kusumi et al. BMC Psychiatry. 2020 Dec 9;20(1):584.

  • Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.

    T.Higuchi et al. Asia Pac Psychiatry. 2020 Mar;12(1):e12377.

  • Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity.

    F. Marchisella et al. Psychopharmacology (Berl). 2020 Jun;237(6):1783-1793.

  • Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.

    N.Iwata et al. CNS Drugs. 2020 Jan;34(1):103-116.

  • Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.

    Philip D Harvey et al. Neuropsychopharmacol Rep. 2020 Mar;40(1):63-72.

  • Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.

    N.Iwata et al. Schizophr Res. 2020 Jan;215:408-415.

    • ＜和文＞

  • 【二次出版】日本人統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の長期間貼付による安全性と有効性　52週間非盲検多施設共同試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.313-336

  • 【二次出版】統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の有効性と安全性の検討　無作為化割付け6週間二重盲検プラセボ対照多施設共同試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.295-312

  • 統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の有効性と安全性の検討:多施設共同、無作為化、二重盲検プラセボ対照試験に続く非盲検継続試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.283-294

2019開く

    ＜英文＞

  • Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia

    Afzal J et al. Neurol Ther. 2019 8:215-230.

  • Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.

    T.Higuchi et al. Asia Pac Psychiatry. 2019 Jun;11(2):e12352.

  • Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.

    T.Higuchi et al. Asia Pac Psychiatry. 2019 Sep;11(3):e12354.

  • Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia.

    S.Takeuchi et al. Neurochem Int. 2019 Sep;128:127-134.

  • Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.

    Philip D.Harvey et al. Neuropsychopharmacol Rep. 2019 Sep;39(3):173-182.

  • Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.

    K.Furuse et al. J Affect Disord. 2019 Mar 15;247:97-104.

  • Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

    T.Masuda et al. JAMA Psychiatry. 2019 Oct 1;76(10):1052-1062.

  • Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    T.Kishi et al. Pharmacopsychiatry. 2019 Feb;52(2):52-62.

  • Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

    T.Kishimoto et al. World Psychiatry. 2019 Jun;18(2):208-224.

    • ＜和文＞

  • 急性増悪期統合失調症患者におけるblonanserin治療反応の早期予測　特定使用成績調査の結果より

    土森紀美子ら　臨床精神薬理, 2019, 22巻12号 P.1223-1235

2018開く

    ＜英文＞

  • Chronic Stress Exposure Reduces Parvalbumin Expression in the Rat Hippocampus through an Imbalance of Redox Mechanisms: Restorative Effect of the Antipsychotic Lurasidone.

    Andrea C.Rossetti et al. Int J Neuropsychopharmacol. 2018 Sep 1;21(9):883-893.

  • Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction.

    L.Ragagopal et al. Behav Brain Res. 2018 Sep 17;350:31-43.

  • Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.

    T.Hashimoto et al. Eur J Pharmacol. 2018 Jul 5;830:26-32.

  • Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

    T.Kishimoto et al. Schizophr Bull. 2018 Apr 6;44(3):603-619.

    • ＜和文＞

  • ドパミンD3受容体遮断による統合失調症の新たな治療の可能性

    井上善文　臨床精神医学, 2018, 47巻3号　P.307-313

2017開く

    ＜英文＞

  • Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial.

    Sramek J et al. Progress in Neuropsychopharmacology & Biological Psychiatry. 2017;78 12-17.

  • Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

    B.Galling et al. World Psychiatry. 2017 Feb;16(1):77-89.

  • Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia.

    M.Huang et al. Pharmacol Biochem Behav. 2017 Jun;157:16-23.

  • Antipsychotics promote GABAergic interneuron genesis in the adult rat brain: Role of heat-shock protein production.

    H.Kaneta et al. J Psychiatr Res. 2017 Sep;92:108-118.

  • Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.

    T.Tsubai et al. J Pharmacol Sci. 2017 Feb;133(2):79-87.

  • Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation.

    A.Luoni et al. Eur Neuropsychopharmacol. 2017 Feb;27(2):170-179.

    • ＜和文＞

  • 急性増悪期統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin投与状況と12週投与の安全性・有効性の検討

    土森紀美子ら　臨床精神薬理, 2017, 20巻11号 P.1311-1334

2016開く

    ＜英文＞

  • Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.

    Jian-Ping Zhang et al. Schizophr Bull. 2016 Nov;42(6):1418-1437.

  • Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.

    F.Misawa et al. Schizophr Res. 2016 Oct;176(2-3):220-230.

  • Variants in the DRD2 locus and antipsychotic-related prolactin levels:A meta-analysis.

    I.Miura et al. Psychoneuroendocrinology. 2016 Oct;72:1-10.

  • Safety and tolerability of antipsychotic cotreatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.

    B.Galling et al. Expert Opin Drug Saf. 2016 May;15(5):591-612.

  • Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment.

    F.Calabrese et al. Pharmacol Res. 2016 Feb;104:140-50.

    • ＜和文＞

  • 糖尿病合併統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin 12ヵ月投与の安全性・有効性の検討

    土森紀美子ら　臨床精神薬理, 2016, 19巻12号 P.1745-1766

  • 統合失調症患者を対象としたblonanserin使用成績調査症例の1年間の追跡調査　日常診療下でのblonanserin長期投与の安全性・有効性の検討

    長尾宗彦ら　臨床精神薬理, 2016, 19巻5号 P.617-631

  • 抗精神病薬未治療の初発統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin 12週投与の安全性・有効性の検討

    川口奈美ら　臨床精神薬理, 2016, 19巻4号 P.471-482

2015開く

    ＜英文＞

  • Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.

    B.Galling et al. Expert Opin Drug Saf. 2015 Aug;14(8):1181-99.

  • Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.

    Philip D.Harvey et al. Schizophr Res. 2015 Aug;166(1-3):334-8.

  • Blonanserin Ameliorates Phencyclidine-Induced Visual-Recognition Memory Deficits: the Complex Mechanism of Blonanserin Action Involving D3-5-HT2A and D1-NMDA Receptors in the mPFC.

    H.Hida et al. Neuropsychopharmacology. 2015 Feb;40(3):601-13.

  • Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.

    A.tatara et al. Pharmacol Biochem Behav. 2015 Nov;138:14-9.

    • ＜和文＞

  • 統合失調症患者に対する日常診療下でのblonanserin 12週投与の安全性・有効性の検討　使用成績調査より

    増田孝裕ら　臨床精神薬理, 2015, 18巻6号 P.769-784

2014開く

    ＜英文＞

  • Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Rat Prefrontal Cortex.

    A.Luoni et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(4):pyu061.

  • Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence.

    A.Luoni et al. Eur Neuropsychopharmacol. 2014 Jun;24(6):986-95.

  • Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.

    A.Luoni et al. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:94-101.

  • Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin.

    Y.Murata et al. Neurosci Lett. 2014 Mar 20;563:123-8.

  • Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

    T.Kishi et al. PLoS One. 2014 Feb 4;9(2):e88049.

2013開く

    ＜英文＞

  • Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.

    A.Luoni et al. Int J Neuropsychopharmacol. 2013 Jul;16(6):1319-30.